PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update

GlobeNewswire
2025.11.13 13:33

Company Announced Completion of VERSATILE-002 Phase 2 trial of PDS0101 + Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Cancer ...